On May 27-28, the Barcelona Science Festival will bring a hundred science activities to the Parc de la Ciutadella.
IRB Barcelona is to participate in the Festival by giving a talk on Network Medicine and holding two workshops for a wide range of public.
What prompts two medical doctors, after six years of training and five years of specialisation, to pursue a PhD? It’s simple: translational medicine.
The bimonthly magazine Clinical OMICs interviews Patrick Aloy, ICREA researcher and leader of the Structural Bioinformatics and Network Biology lab at IRB Barcelona, about his study published in the journal Cancer Research. Patrick Aloy talks about his work as a leader of team that uses bioinformatics approaches to uncover new drug combinations for the treatment of breast cancer.
Patrick Aloy, ICREA researcher at IRB Barcelona, has told the programme 'L'Entrevista', broadcasted by “La Xarxa Televisió”, that research into Alzheimer’s disease is still unravelling the disease, how it starts and what would be a suitable approach to tackle it."
Because of the complexity of this condition, Aloy says, "we will not cure Alzheimer’s disease. We have to focus on halting its progression. The earlier we stop the development of this condition, the greater the improvement in the health of those who suffer from it."
"To halt its progression, we will be able to administer drugs when symptoms of the disease are...
The local newspaper “Regió 7” devotes an article to the study headed by Patrick Aloy, ICREA researcher and leader of the Structural Bioinformatics and Network Biology lab at IRB Barcelona. The study has found 10 previously untested drug combinations with potential to tackle resistance to breast cancer treatment.
Link to Regió 7
United Press International publishes an extensive article about the study headed by Patrick Aloy, ICREA researcher and leader of the Structural Bioinformatics and Network Biology Lab at IRB Barcelona.
Published in Cancer Research Journal, the study reveals a new way to fight drug resistance in the treatment of breast cancer through bioinformatics.
Link to UPI
Other media mentions:
A bioinformatics analysis of pairing 64 drugs used to treat breast cancer allows researchers at IRB Barcelona to identify 10 previously untested combinations with potential to tackle resistance to breast cancer treatment.
In spite of the many drugs available to treat breast cancer, resistance continues to be a problem.
EFE Agency has echoed the research performed by Carles Pons, Research Associate in Patrick Aloy's lab (Structural Bioinformatics and Network Biology) at IRB Barcelona, recently published in Science. The study presents the first comprehensive set of suppressive mutations in a cell. Its findings could help “explain how suppressive mutations combine with disease-causing mutations to soften the blow of a disease, or even completely protect against it”.
Link to EFE Agency
Eduard Batlle’s work on colon cancer and Patrick Aloy’s on the network biology of Alzheimer’s disease feature among the newspaper El Mundo’s list of the most promising ten lines of research performed in labs in Spain. These ten labs are recognised as having the capacity to provide new pieces of the puzzle and transform some aspects of our everyday lives. The newspaper drew up the list on the occasion of Researchers’ Night.